Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Acrux ( (AU:ACR) ) just unveiled an update.
Acrux Limited has received a $0.46 million advance from Radium Capital as part of its FY25 R&D Tax Incentive, bringing the total advances to $2.19 million. This funding provides early access to the RDTI rebate, which will support the development of products and management of working capital, highlighting Acrux’s strategic use of financial resources to bolster its operations.
More about Acrux
Acrux is a specialty pharmaceutical company that focuses on developing and commercializing topically applied pharmaceutical products. With 25 years of experience, Acrux has successfully marketed products worldwide, particularly in the United States. The company leverages its skilled workforce, on-site laboratories, and GMP manufacturing suite to formulate and develop affordable topical generic products. Acrux is open to collaboration and commercial partnerships for product development opportunities.
Average Trading Volume: 313,279
Technical Sentiment Signal: Sell
Current Market Cap: A$7.34M
Find detailed analytics on ACR stock on TipRanks’ Stock Analysis page.